Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy

European Journal of Cancer

Volumn 51, Issue 17, 2015, Pages 2678-2685

  Spindler, Karen Lise Garm ^a,b   Pallisgaard, Niels ^b   Appelt, Ane Lindegaard ^b   Andersen, Rikke Fredslund ^b   Schou, Jakob V ^c   Nielsen, Dorte ^c,f   Pfeiffer, Per ^d   Yilmaz, Mette ^e   Johansen, Julia S ^c,f   Hoegdall, Estrid V ^c   Jakobsen, Anders ^b   Jensen, Benny V ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cetuximab; cfDNA; Metastatic colorectal cancer; Plasma KRAS; Prognosis

Indexed keywords

CETUXIMAB; CIRCULATING CELL FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PARAFFIN; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; COMPARATIVE STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TISSUE FIXATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE FIXATION;

EID: 84969850205     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.06.118     Document Type: Article

References (31)

1. P. Mandel, and P. Metais Les acides nucleiques du plasma sanguin chez l'homme CR Seances Soc Biol Fil 142 1948 241 243
2. S. Jahr, H. Hentze, S. Englisch, D. Hardt, F.O. Fackelmayer, and et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells Cancer Res 61 2001 1659 1665
3. F. Diehl, M. Li, D. Dressman, Y. He, D. Shen, S. Szabo, and et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors Proc Natl Acad Sci USA 102 2005 16368 16373
4. M. Stroun, J. Lyautey, C. Lederrey, A. Olson-Sand, and P. Anker About the possible origin and mechanism of circulating DNA apoptosis and active DNA release Clin Chim Acta 313 2001 139 142
5. E. Gormally, E. Caboux, and P. Vineis Hainaut P circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance Mutat Res 635 2007 105 117
6. Y.H. Su, M. Wang, D.E. Brenner, and P.A. Norton Block TM Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps Ann N Y Acad Sci 1137 2008 197 206
7. S.A. Leon, B. Shapiro, D.M. Sklaroff, and M.J. Yaros Free DNA in the serum of cancer patients and the effect of therapy Cancer Res 37 1977 646 650
8. G. Perkins, T.A. Yap, L. Pope, A.M. Cassidy, J.P. Dukes, R. Riisnaes, and et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 7 11 2012 e47020
9. M. van der Vaart, and P.J. Pretorius Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 43 2010 26 36
10. L. De Mattos-Arruda, D. Olmos, and J. Tabernero Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer Future Oncol 7 2011 1385 1397
11. L.X. Qiu, C. Mao, J. Zhang, X.D. Zhu, R.Y. Liao, K. Xue, and et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies Eur J Cancer 46 2010 2781 2787
12. R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D.J. Freeman, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
13. A.I. Phipps, D.D. Buchanan, K.W. Makar, A.K. Win, J.A. Baron, N.M. Lindor, and et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers Br J Cancer 108 2013 1757 1764
14. A.D. Roth, S. Tejpar, M. Delorenzi, P. Yan, R. Fiocca, D. Klingbiel, and et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474
15. T. Yokota Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 12 2012 163 171
16. K.G. Spindler, A.L. Appelt, N. Pallisgaard, and R.F. Andersen Jakobsen A.KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer Br J Cancer 109 2013 3067 3072
17. K.L. Spindler, N. Pallisgaard, I. Vogelius, and A. Jakobsen Quantitative cell free DNA, KRAS and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan Clin Cancer Res 18 2012 1177 1185
18. T.S. Maughan, R.A. Adams, C.G. Smith, A.M. Meade, M.T. Seymour, R.H. Wilson, and et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
19. K.M. Tveit, T. Guren, B. Glimelius, P. Pfeiffer, H. Sorbye, S. Pyrhonen, and et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study J Clin Oncol 30 2012 1755 1762
20. L.A. Diaz Jr, R.T. Williams, J. Wu, I. Kinde, J.R. Hecht, J. Berlin, and et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540
21. S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
22. F. Diehl, K. Schmidt, M.A. Choti, K. Romans, S. Goodman, M. Li, and et al. Circulating mutant DNA to assess tumor dynamics Nat Med 14 2008 985 990
23. L.C. Yen, Y.S. Yeh, C.W. Chen, H.M. Wang, H.L. Tsai, C.Y. Lu, and et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer Clin Cancer Res 15 2009 4508 4513
24. S.R. Morgan, J. Whiteley, E. Donald, J. Smith, M.T. Eisenberg, E. Kallam, and et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples Clin Med Insights Pathol 5 2012 15 22
25. R.F. Andersen, K.L. Spindler, I. Brandslund, A. Jakobsen, and N. Pallisgaard Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons Clin Chim Acta 439 2015 97 101
26. J. Tie, I. Kinde, Y. Wang, H.L. Wong, J. Roebert, M. Christie, and et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer Ann Oncol 2015 [Epub ahead of print]
27. M.P. Morelli, M.J. Overman, A. Dasari, S.M. Kazmi, T. Mazard, E. Vilar, and et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment Ann Oncol 26 2015 731 736
28. T. Reinert, L.V. Schøler, R. Thomsen, H. Tobiasen, S. Vang, I. Nordentoft, and et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery Gut 2015 [Epub ahead of print]
29. K.L. Spindler, N. Pallisgaard, R.F. Andersen, I. Brandslund, and A. Jakobsen Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer PLoS One 2015 e0108247
30. K.L. Spindler, A.L. Appelt, N. Pallisgaard, R.F. Andersen, I. Brandslund, and A. Jakobsen Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer Int J Cancer 135 2014 2984 2991
31. A.R. Thierry, F. Mouliere, S. El Messaoudi, C. Mollevi, E. Lopez-Crapez, F. Rolet, and et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat Med 20 2014 430 435